Objectives: To determine the net health consequences, costs, and cost-effectiveness of alternative delivery strategies for HIV-infected pregnant women with detectable HIV RNA in the USA.
Introduction
The majority of pediatric HIV infections are acquired via mother-to-child transmission [1] . Since women of childbearing age represent the fastest growing segment of adults with HIV and AIDS in the USA [2] , the number of infants at risk for HIV infection may increase. The majority of mother-to-child HIV trans-missions occur at or around the time of delivery [3, 4] and risk of transmission is associated with longer times between rupture of the membranes and delivery [5, 6] . These issues suggest that Cesarean delivery might reduce the risk of vertical transmission of HIV.
Several studies have evaluated the ef®cacy of elective cesarean delivery in reducing vertical transmission of HIV [7±10] . Two prospective cohort studies of elective Cesarean section showed signi®cant reductions in transmission rates of HIV, especially with concurrent zidovudine therapy [7, 8] . A meta-analysis by the International Perinatal HIV Group showed that the adjusted odds ratio for transmission with elective Cesarean section was 0.43 (95% con®dence interval, 0.33±0.56) [9] . That same analysis also showed that with concurrent zidovudine therapy, vertical transmission rates were reduced even further (odds ratio, 0.27) [9] . A European randomized controlled trial showed signi®cant reduction in transmission, as well, with an odds ratio of 0.2 (95% con®dence interval, 0.1±0.6) for elective Cesarean delivery [10] .
Despite the demonstrated bene®t of elective Cesarean section and the recommendation by the American College of Obstetricians and Gynecologists that elective Cesarean delivery be discussed with all HIV-infected pregnant women in the USA, its use is controversial [11, 12] . There have been two main arguments raised in opposition to Cesarean delivery. First, is that the studies of the ef®cacy of Cesarean section in reducing vertical transmission were performed before highly active antiretroviral therapy (HAART) became standard, and thus there is some uncertainty regarding the incremental bene®t of Cesarean section compared with HAART alone [12] . Second, is that higher complication rates have been reported in association with Cesarean section in HIV-infected women [12] .
Two recent studies showed that vertical transmission of HIV occurs predominantly in women with detectable HIV RNA levels during pregnancy [13, 14] . Recent randomized controlled trials of antiretroviral therapies have shown that HIV RNA remains detectable in 10± 40% of patients receiving HAART; community studies report that HIV RNA remains detectable in more than 60% of patients on therapy [15, 16] . Studies use varying de®nitions for`undetectable'. In the present analysis, undetectable' was de®ned as by Mofenson et al.: , 500 copies/ml [13] .
Given current treatment failure rates, problems with access to care, and dif®culty with adherence to HAART, the percentage of women with detectable HIV RNA in pregnancy will continue to be substantial. The objective of this analysis was to quantify the risks, bene®ts, and costs associated with the strategy of delivery by elective Cesarean section at 38 weeks gestation versus the strategy of vaginal delivery at term for pregnant HIV-infected women with detectable HIV RNA and their offspring. In addition, we wished to examine explicitly the effect that lower vertical transmission rates with vaginal delivery (as might be seen with HAART), higher Cesarean section complication rates, and maternal preferences for vaginal versus Cesarean delivery would have on the results.
Methods

Decision analytic model
Using the decision analysis software program DATA, version 3.5 (TreeAge Software, Inc., Williamstown, Massachusetts, USA) a decision analytic model was developed to calculate lifetime costs and qualityadjusted life expectancy associated with strategies for delivering pregnant HIV-infected women who have detectable HIV RNA (Fig. 1 ). The two strategies considered were elective Cesarean section and vaginal delivery. Under the elective Cesarean strategy, most women deliver by elective Cesarean section; however, some still go into labor before 38 weeks and deliver vaginally or require urgent Cesarean delivery. In the trial of labor strategy, the majority of women deliver vaginally, but some undergo either an urgent or an elective Cesarean section. Women may survive delivery with or without complications or may die. Regardless of maternal outcome, it is possible for the infants to become infected with HIV.
Each delivery mode is associated with a unique maternal death rate, vertical transmission rate, and cost. To compare the outcomes of these strategies, the incremental cost-effectiveness ratio was calculated, de-®ned as the difference in cost divided by the difference in bene®t. The maternal mortality and HIV transmission rates expected with each strategy were also reported. Based on the recommendations of the Panel on Cost-effectiveness in Health and Medicine, a reference case analysis was included, a societal perspective was adopted, all costs and clinical bene®ts were discounted at a rate of 3% per year to facilitate comparison with other cost-effectiveness analyses [17] .
Model parameters
Delivery rates Estimates for the rates of delivery were taken from the randomized trial of elective Cesarean section published by The European Mode of Delivery Collaboration (Table 1 ) [10] .
Mortality by type of delivery
The maternal death rates for vaginal, elective Cesarean, and urgent Cesarean deliveries were determined using published literature and hazard rates were adjusted to 1997 rates using maternal mortality trends [18±22]. It was assumed that women with HIV/AIDS had the same delivery-speci®c mortality rates as uninfected women, but that assumption was relaxed in sensitivity analyses.
Vertical transmission rates
Vertical transmission rate was assumed to be dependent on the presence of detectable HIV RNA in the mother regardless of antiretroviral regimen. For the base case analysis, data on the HIV transmission rate with vaginal delivery in women with detectable HIV RNA were derived from Mofenson et al. and assumed to be constant (6.7%) [13] . In the sensitivity analysis, data derived from Garcia et al. in which transmission rate (16.6%±40.6%) was strati®ed by HIV RNA level were used [14] . In the baseline analysis the lower transmission rate reported by Mofenson et al. was used which biased the analysis against the Cesarean section strategy.
The relative risk of transmission associated with elective Cesarean section was based on results of the metaanalysis from the International Perinatal HIV Group [9] . Although this relative risk (0.43) was less favorable than that reported by the European Mode of Delivery Collaboration trial (0.3) [10] , it was chosen for use in the base case, again biasing the analysis against the Cesarean section strategy. The HIV transmission rate associated with urgent Cesarean section was based on data from the European Mode of Delivery Collaboration trial [10] . In sensitivity analyses, transmission rates were varied over a wide range based on data from these and other studies [7±10, 23, 24] .
Complication rates
Three small studies and the European Mode of Delivery Collaboration trial have shown higher rates of minor complications (fever, endometritis, urinary tract infection, and wound infection) in postpartum women with HIV [10,25±27] . The highest morbidity rates reported in these studies were assumed in this model [26] .
Quality-adjusted life expectancy
Outcomes were projected for a hypothetical cohort of 25-year-old HIV-infected women living in the USA. In this analysis, it was assumed that women had been infected with HIV for 5 years at the time of delivery but did not yet have AIDS. To calculate qualityadjusted life expectancy, life expectancy estimates were multiplied by utilities, or quality-of-life weights, which can range from 0.0 (death) to 1.0 (perfect health). In the base case analysis, maternal quality-adjusted life expectancy was calculated using estimates for both utilities and life expectancy (21 years) from an analysis by Holtgrave et al. (Appendix 1) [28] . To estimate the lower-bound of the plausible range, data from that same analysis was used, which re¯ected less intensive antiretroviral therapy than is now standard [28] . To estimate the upper-bound, higher published utility estimates were incorporated and it was assumed that normal life expectancy would be shortened by HIV infection by only 10 years [29, 30] . It was assumed that the dysutility from undergoing a Cesarean section would be equivalent to the loss of 1 week of life. In sensitivity analysis the dysutility was varied from no decrement in quality-adjusted life expectancy to the loss of 3 quality-adjusted months. It was assumed that there would be no long-term effect of mode of delivery on maternal health given the short duration of the complications noted in the referenced studies [10,25±27] , but a decrement in utility, or dysutility, was assignes to women with delivery complications. It was assumed that having complications from delivery would be equivalent to the loss of 1 quality-adjusted week. In sensitivity analysis, this dysutility was varied from no decrement to 3 quality-adjusted months.
For HIV-infected infants, a life expectancy of 15 years was assumed and quality-adjusted life expectancy was calculated assuming utility estimates similar to those reported by Holtgrave et al. [28] . To estimate the lower bound of the plausible range of quality-adjusted life expectancy, data re¯ecting life expectancy prior to the availability of HAART [29] were used. An upperbound life expectancy of 50 years was assumed and higher published utility estimates [30, 31] were incorporated in another sensitivity analysis.
For uninfected infants, life expectancy was estimated using a published national estimate for newborns [32] . Age-adjusted utility estimates from the Beaver Dam Health Outcomes Study [31] were used, which reported sex-speci®c data for people aged more than 45 years. Because this study did not report utilities for persons aged less than 45 years, it was assumed that the utility for non-HIV-infected people aged less than 45 years was 1.0.
Costs
Annual cost estimates for HIV-infected children were derived from charges obtained from the AIDS Cost and Service Utilization Survey (ACSUS) [33] . Because these data re¯ect the standard of care prior to HAART and routine viral load testing, costs were updated by adding the cost of a second reverse transcriptase inhibitor (average cost for zidovudine, didanosine, lamivudine, and stavudine), a protease inhibitor (average cost for ritonavir and nel®navir), and quarterly viral load testing. Drug costs were obtained from the Red Book [34] and adjusted for overstatement of acquisition costs [35] . A monthly dispensing cost was also added [36] . Costs associated with viral load testing were obtained from a study by Rawlings et al. [37] .
Using these component costs and assuming the yearly treatment costs associated with AIDS (as opposed to HIV infection without AIDS) in the last 2 years of life only, average updated annual costs were derived in a manner similar to that used by Holtgrave et al. [28] .
For the lower bound of the plausible range, lifetime costs from Hsai et al. were used which re¯ect care during the antiretroviral monotherapy era [33] . For the upper bound, estimates from Havens et al. were modi®ed in the same manner as for the baseline costs [29] . The ACSUS derived HIV-associated charges were converted to costs by using a cost-to-charge ratio of 0.6, as did Freedberg et al. [38] . Costs were in¯ated to 1997 dollars using the Consumer Price Index for medical care and all future costs were discounted at a 3% annual rate. The discount rate was varied from 0% to 10% in sensitivity analysis.
Costs were determined for each mode of delivery with and without complications. Delivery costs were based on an average of the total costs for deliveries performed in ®scal year 1997 at an urban teaching hospital, obtained using the hospital's cost accounting system (McKesson/HBOC, Atlanta, Georgia, USA). Total costs were used instead of variable costs to be consistent with the HIV-associated costs from the ACSUS data set.
Sensitivity analyses
Univariate and multivariate sensitivity analyses were used to assess the stability of the results to the underlying data and assumptions. In this model, the relative risk of death, the relative risk of transmission, and the costs for the three modes of delivery (vaginal, elective Cesarean section, and urgent Cesarean section) were constrained to maintain their relative order in sensitivity analyses. For example, in the absence of complications, vaginal delivery costs were not permitted to exceed elective Cesarean section costs, and elective Cesarean section costs could not exceed urgent Cesarean section costs.
Results
Base case results
The elective Cesarean section strategy resulted in 34.9 infected infants per 1000 deliveries, 14.7 maternal deaths per 100 000 deliveries, and 38.7 quality-adjusted life years (QALYs) per mother±child pair at a cost of $10 600 ($4500 in delivery costs plus $6100 in discounted future medical costs) per birth ( 
Sensitivity analyses
It was found that elective Cesarean delivery was more effective and less costly than vaginal delivery over a wide range of assumptions (Appendix II). Two important thresholds were identi®ed in sensitivity analyses: (i) the HIV transmission rate with vaginal delivery (base case rate, 6.7%) and (ii) the relative risk of HIV transmission with elective Cesarean delivery (base case, 0.43). Nevertheless, the results were stable over most of the range of these parameters. Only when the transmission rate fell below 1.3% or the relative risk of transmission with elective Cesarean delivery exceeded 0.89, did the elective Cesarean delivery strategy cost more than the vaginal delivery strategy. Even in these extreme cases, the elective Cesarean delivery strategy was associated with a gain in quality-adjusted life expectancy (Table 3 ). Varying these two parameters simultaneously in a two-way sensitivity analysis showed that the relative risk of HIV transmission with elective Quality-adjusted life expectancy for child (years)
28. 9 28.4 a In the baseline analysis, maternal quality-adjusted life years were 0.016 greater with the vaginal delivery strategy than with the elective cesarean section strategy. Cesarean section exerts its greatest in¯uence at vaginal HIV transmission rates below 1% (Fig. 2) . The results of this analysis were insensitive to increasing the probability of maternal death from Cesarean delivery (to test the hypothesis that HIV-infected women have higher perinatal mortality), the relative risk of complications from elective Cesarean section, or the dysutility associated with Cesarean section and its complications (Appendix II).
Discussion
There is substantial evidence that elective Cesarean section can decrease vertical transmission of HIV [7± 10]; however, it has not been determined whether elective Cesarean section would offer incremental clinical bene®ts and be cost-effective compared with antiretroviral therapy. The present results showed that over a broad range of values and several conservative assumptions biasing the analysis in favor of the vaginal delivery strategy, the elective Cesarean section strategy was associated with increased quality-adjusted life expectancy and lower costs compared with the vaginal delivery strategy, for women with detectable HIV RNA during pregnancy.
Some of the controversy surrounding elective Cesarean delivery in pregnant women with HIV infection has centered on maternal mortality and morbidity [12, 40] .
When it was assumed that delivery-speci®c mortality would be the same for both HIV-infected and uninfected women, the model used predicted only one additional maternal death every 20 years. Neither varying the probability of maternal death from Cesarean delivery nor varying the relative risk of complications with Cesarean delivery over plausible ranges yielded major changes in the overall outcomes.
Ratcliffe et al. analyzed the cost-effectiveness of three interventions to reduce vertical transmission of HIV: bottle-feeding, zidovudine therapy for the mother and child, and Cesarean section [41] . They reported that for elective Cesarean section, the incremental cost per transmission avoided relative to vaginal delivery was £27 836 (1996 currency) assuming universal zidovudine therapy. When actual zidovudine usage rates from the UK were incorporated, the incremental cost per transmission avoided fell to £18 546 for elective Cesarean delivery. Although their cost estimates, transmission rates, and outcomes differ from those used here, the conclusions of the two studies are consistent. The present analysis expanded the efforts of Ratcliffe et al. in several ways: (i) more recent vertical transmission data were used; (ii) maternal morbidity and mortality were incorporated; (iii) QALYs were used as a measure of effectiveness; (iv) data pertaining to the USA were used; and (v) reference case analysis was used as recommended by the Panel on Cost-Effectiveness in Health and Medicine [17] .
A more recent analysis by Halpern et al. [42] looked speci®cally at the cost effectiveness of elective Cesarean delivery for HIV-infected women delivering in the USA. Their analysis showed that for women delivering without concurrent antiretroviral therapy, elective Cesarean delivery prevented HIV-infections and was cost saving. For women receiving concurrent zidovudine and combination antiretroviral therapy in pregnancy, they showed that elective Cesarean delivery was costeffective, but was no longer cost saving. They estimated that Cesarean delivery would cost $17 per year of life saved for women taking zidovudine and $1697 per year of life saved for women taking combination therapy.
While the present study approached the risk of transmission differently (it was based on maternal viral load instead of maternal antiretroviral therapy), the results agree with those of Halpern et al. [42] : elective Cesarean delivery is an economically and clinically viable option to prevent vertical transmission of HIV. Both this study and that of Halpern et al. also agree that the cost-effectiveness of Cesarean delivery is sensitive to variations in vertical transmission rates but not to variations in post-partum morbidity rates. These results differ from those of Halpern et al. regarding only whether elective Cesarean delivery is cost saving or not. The difference in outcome is due in large part to a difference in input cost estimates: the procedure-related costs used in this study represented actual total costs whereas those of Halpern et al. represented charges, and therefore were signi®cantly higher. Also, the lifetime costs for children infected with HIV were higher in this study because it was assumed that patients would take highly active antiretroviral therapy (rather than monotherapy) and have a longer life expectancy. Both A recent community study showed that less than 40% of patients had persistent undetectable HIV RNA [15] . We believe that because of issues of antiretroviral resistance, incomplete adherence, dif®culty with treatment access, and late diagnosis of HIV, many women will potentially have detectable HIV RNA during their pregnancy. The optimal strategy for this subset of women was the focus of this analysis. Based on currently available data, it was found that over a wide range of assumptions, elective Cesarean section for pregnant HIV-infected women with detectable HIV RNA is both more effective and less costly than routine vaginal delivery. We believe that this issue will have to be re-addressed as new information becomes available, especially as it relates to relative transmission rates with combination therapy; however, based on currently available data, we believe that elective Cesarean delivery should be offered to HIV-infected pregnant women with detectable HIV RNA to decrease their probability of mother-to-child HIV transmission. HIV-infected, without AIDS, on therapy, age 45±50 years 0.92 31 a Assumes that the mother is 25 years old and has been HIV-infected for 5 years at time of pregnancy. b Baseline estimates assume use of highly active antiretroviral therapy. c Lower-bound estimates assume no use of highly active antiretroviral therapy. d Upper-bound estimates assume use of highly active antiretroviral therapy, a life expectancy of 50 years after HIV infection, and relatively high utility values. 
